Gideon Rechavi received an MD from Tel‑Aviv University in 1981 and a PhD from the Weizmann Institute of Science. He is board certified in Hematology, Pediatrics, and Pediatric Hematology-Oncology. He is Professor of Hematology and holds the Djerassi Chair in Oncology, Tel Aviv University. He served as head of the Division of Hematology, Sackler School of Medicine and as head of the Tel Aviv University Cancer Biology Research Center.
In 1992 he was appointed head of the Pediatric Hematology‑ Oncology and Bone Marrow Transplantation Department at the Sheba Medical Center and in 1999 he established the Sheba Cancer Genomics Unit, a leading Israeli center for medical genomics. In 2003 he established the Sheba Cancer Research Center, which he heads and from 2016 he heads the Wohl Institute for Translational Medicine.
His main research interests are RNA epigenetics, transposable genetic elements and cancer genomics with special emphasis on pediatric cancer. In recent years, his laboratory became a leading facility for genomic analysis where genes involved in a variety of monogenic diseases are identified. His group is now involved in the study of “orphan” genetic diseases aiming at the development of individualized genetic therapy.
He has published 500 articles in the most prestigious journals including Nature, Cell, Science, New England Journal of Medicine, Lancet and many more.
He has been awarded numerous prizes and research grants including the EMET prize for Genetics and an ERC Advanced Grant. He was selected for the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine.
Rechavi is a member of the European Academy of Cancer Sciences and a member of the Israeli Academy of Sciences. He was awarded the Israel Prize in Medical Research in 2020.